Evidence map›Paper›PMID 41071504›Full record

ArticleAIDS and behavior2026

Barriers to Same-Day Pre-exposure Prophylaxis (PrEP) Implementation in Federally Funded HIV Clinics Within High-Burden Areas of the U.S.: A Coincidence Analysis.

Alithia Zamantakis, Wilson Gomez, Lipin Lukose, Ana Michaela Pachicano, Jessica Kassanits, Anna-Sophia Katomski, Elena P Rosenberg-Carlson, Cathleen E Willging, LaRon E Nelson, Tequetta Valeriano and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Alithia ZamantakisInstitute for Sexual and Gender Minority Health and Wellbeing, Northwestern University, Chicago, IL, USA. alithia.zamantakis@northwestern.edu.ORCID http://orcid.org/0000-0002-8030-2775
Wilson GomezDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0009-0008-3751-7907
Lipin LukoseDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Ana Michaela PachicanoInstitute for Sexual and Gender Minority Health and Wellbeing, Northwestern University, Chicago, IL, USA.
Jessica KassanitsInstitute for Sexual and Gender Minority Health and Wellbeing, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0009-0005-0368-2953
Anna-Sophia KatomskiDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Elena P Rosenberg-CarlsonCenter for HIV Identification, Prevention, and Treatment Services, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0009-0008-5654-9728
Cathleen E WillgingPacific Institute for Research and Evaluation, Albuquerque, NM, USA.
LaRon E NelsonCenter for Methods in Implementation and Prevention Science, School of Nursing, Yale University, New Haven, CT, USA.
Tequetta ValerianoCenter for Methods in Implementation and Prevention Science, School of Nursing, Yale University, New Haven, CT, USA.
Maile KarrisDivision of Infectious Diseases, School of Medicine, University of California San Diego, San Diego, CA, USA.
Jill S BlumenthalDivision of Infectious Diseases, School of Medicine, University of California San Diego, San Diego, CA, USA.
Aadia I RanaDivision of Infectious Diseases, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Russell A BrewerChicago Center for HIV Elimination, University of Chicago, Chicago, IL, USA.
Alison HamiltonDepartment of Psychiatry and Biobehavioral Sciences, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Christopher KempDepartment of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Debbie HumphriesSchool of Public Health, Yale University, New Haven, CT, USA.
Nanette D BenbowInstitute for Sexual and Gender Minority Health and Wellbeing, Northwestern University, Chicago, IL, USA.
Uyen KaoCenter for HIV Identification, Prevention, and Treatment Services, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Sung-Jae LeeCenter for HIV Identification, Prevention, and Treatment Services, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Joyce L JonesDivision of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Sheree R SchwartzDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Laura K BeresDepartment of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Joseph G RosenDivision of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-4991-4033

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sung-Jae Lee · 1997 to 2026
$53.5M
Using Coincidence Analysis to Investigate Factors Affecting PrEP Initiation and Continuation in Southern ending the Epidemic CountiesP30MH062294 · NIMH · YALE UNIVERSITY · PI Trace S Kershaw · 2001 to 2026
$48.5M
Virology and Immunology Technology CoreP30AI117943 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Sahera Dirajlal-Fargo · 2015 to 2026
$38.4M
Project 4: Neonatal Abstinence Syndrome (NAS): Fetus to First YearsP20GM125507 · NIGMS · RHODE ISLAND HOSPITAL · PI CURT G BECKWITH · 2018 to 2026
$23.4M
The Brown Initiative in HIV and AIDS Clinical Research for Minority CommunitiesR25MH083620 · NIMH · MIRIAM HOSPITAL · PI NUNN, AMY STEWART · 2008 to 2025
$3.7M
UCLA Rapid, Rigorous, Relevant Implementation Science Hub: Leveraging Implementation Science to End the HIV EpidemicR24AI191868 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALISON B. HAMILTON · 2025 to 2026
$1.4M
Optimizing implementation of long-acting, injectable Cabotegravir for HIV prevention among adolescents and young adults in ZambiaK01MH130244 · NIMH · JOHNS HOPKINS UNIVERSITY · PI BERES, LAURA · 2022 to 2025
$696k
NCATS NIH HHS UL1 TR001422NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI094189NIAID NIH HHS P30 AI117943NIAID NIH HHS R24 AI191868NIGMS NIH HHS P20 GM125507NIH HHS P30AI117943, P30AI094189, P30MH062294, P30MH058107, P30AI036214, P30AI027767NIMH NIH HHS K01 MH130244NIMH NIH HHS P30 MH058107NIMH NIH HHS P30 MH062294NIMH NIH HHS R25 MH083620
6 · The paper itself

Abstract

backgroundSame-day pre-exposure prophylaxis (PrEP) for HIV prevention is a novel tool to increase biomedical prevention access and uptake. Although prior research has identified same-day PrEP as feasible and acceptable, improved understanding of key barriers and facilitators to implementation is needed to optimize impact.

methodsThe Network for Implementation Science in HIV (NISH) examined the implementation of same-day PrEP across 42 Ryan White Part A-D-funded organizations in seven Ending the U.S. HIV Epidemic Initiative priority jurisdictions. We used crisp-set coincidence analysis with six conditions to identify key barriers explaining delayed implementation of same-day PrEP among 38 clinical organizations representing 137 individual clinics where same-day PrEP services were available currently or in the future.

resultsOur final model explained ~ 67% of clinical organizations not currently implementing same-day PrEP (n = 8), with a consistency of 80%. This model identified three pathways to non-implementation of same-day PrEP: (1) insurance coverage as a top barrier and insufficient staffing resources as a top barrier; (2) no onsite pharmacy as a top barrier; or (3) provider reticence with same-day PrEP prescribing and insurance coverage as top barriers, and patient demand/(dis)interest in same-day PrEP not being ranked as a top barrier.

conclusionThe three identified pathways to delayed implementation of same-day PrEP aid researchers and providers in reverse mapping strategies to enhance and scale up the implementation of same-day PrEP in federally funded clinics in the U.S. Such strategies may include federal and state-level policy changes to expand funding for PrEP coverage, pharmacist-led same-day PrEP implementation, or mail delivery of PrEP prescriptions.

Indexed as

Ambulatory Care FacilitiesAnti-HIV AgentsHealth Services AccessibilityHIV InfectionsPre-Exposure ProphylaxisFinancing, GovernmentHumansUnited StatesAnti-HIV AgentsBiomedical HIV preventionConfigurational analysisEnding the HIV epidemicImplementation scienceSame-day PrEPUnited states

Identifiers

PMID41071504
PMCPMC12765568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.